UK polynucleotide institutional position register

This register records whether named UK institutions have published material that specifically addresses polynucleotide injectables, or only wider rules that may matter around them. As read on 8 November 2026, it identifies a gap between general cosmetic-injection governance and dedicated institutional information on polynucleotides.

What this register records

This is a dated institutional register, not a clinical evidence summary and not a directory of practitioners. It asks a narrow question: has a named UK institution published a position, guidance document or patient information that specifically addresses polynucleotide injectables? Where the answer is no, the register records the nearest relevant institutional material and states its limit.

That distinction matters. A document about medicines, medical devices, advertising, professional conduct or cosmetic procedures can affect the circumstances in which an injectable is supplied, prescribed, advertised or administered. It does not necessarily establish a position on polynucleotides as a substance class. A reader should not turn a general rule into an implied endorsement, prohibition or clinical conclusion about this particular injectable.

The register was read on 8 November 2026. "No dedicated position located" means that this register did not identify a publication by that body using the term polynucleotides, polynucleotide injectable, PN or PDRN in the body's relevant public material reviewed for this purpose. It is not proof that no internal advice, local policy, correspondence or later publication exists.

For the evidence behind clinical propositions, read the publication's Evidence Register. For the separate question of the UK legal and professional framework around injecting, read its UK Position on Who May Inject. This page does not restate either resource, and it makes no claim about effectiveness.

The practical value of the register is negative as well as positive. A patient may reasonably expect prominent health, professional and regulatory bodies to have a polynucleotide-specific statement. In many cases, the material currently available is instead general material that applies according to a product's classification, a professional's role, the setting and the wording of any claim.

Institutional position register

The table uses deliberately cautious wording. "Specific" means that the named document is directed at polynucleotides or PDRN. "General only" means that the cited publication may be relevant to an injectable procedure but does not set out a substance-specific position. "No dedicated position located" is a finding of this register as at the read date, rather than a statement about every possible publication held by the institution.

None of the entries above should be read as a statement that a body approves, recommends or rejects a particular product. The table records the scope of published material, not an inferred institutional view.

How to read a general document without overstating it

A general institutional document can still matter, but it must be read at its own level. Medical-device guidance concerns the legal framework for products that meet the definition of a device. Professional standards concern the conduct and competence of particular registrants. Advertising rules concern claims made to the public. Service-regulation material concerns whether an activity falls within a regulator's legal remit. These are separate questions.

A useful decision rule is to match the reader's question to the document's subject before drawing any conclusion.

This separation is especially important where a clinic, supplier or commentator cites an institutional logo or a broad professional standard. The cited material may be real and relevant, yet the claimed conclusion may go further than the document does. Ask for the title of the publication, the exact passage relied on, its date and the proposition it is said to support.

A document can also change status. Consultations invite views and do not themselves create a rule. Codes set standards for their registrants but do not automatically govern everybody working in a cosmetic setting. Guidance may explain an existing framework rather than announce a new classification. This register therefore reports documents descriptively and avoids collapsing them into a single answer.

Bodies a patient might expect to address polynucleotides

Patients may expect a national health body, a medicines regulator, a clinical-guideline body and professional regulators to publish direct material because polynucleotides are injected and are often discussed within cosmetic medicine. That expectation is understandable. It does not follow that each body has a mandate to issue a substance-specific view, or that the absence of one carries a clinical meaning.

The National Institute for Health and Care Excellence is often expected to provide a decisive answer because it publishes influential guidance. Its work, however, is commissioned and scoped. A search finding no dedicated guidance is not a finding that the intervention has been assessed and rejected. Equally, a lack of guidance is not positive evidence. It leaves the evidence question to the underlying literature and to the limits of available assessment.

The National Health Service may be expected to provide patient information. Its public information is not a complete catalogue of all private cosmetic procedures or injectable substances. The absence of a dedicated page should therefore be treated as an information gap, not a personal suitability assessment.

The Medicines and Healthcare products Regulatory Agency is expected to matter because product status and claims can affect regulatory treatment. Its general framework is important, but a reader needs to distinguish framework guidance from a public, product-by-product opinion. Product classification and compliance cannot safely be established from promotional wording or from a generic label such as "medical grade".

Professional regulators are also expected to have a view. Their central function is typically to set standards for people on their register. Their general documents can be highly relevant to records, consent, competence, delegation and medicines practice, while still saying nothing specifically about polynucleotides.

What the register does and does not establish

This register establishes only the presence, absence or limited scope of identified public institutional material at the stated date. It does not determine whether an individual product is a medical device, medicine, cosmetic or another category. Those questions turn on facts such as composition, intended purpose, presentation, supply route and applicable law. They should not be answered by assuming that all products described using the same treatment term have identical status.

It does not decide who may inject. The legal position can depend on the UK nation, the person's professional status, whether a prescription-only medicine is involved, the setting, local requirements and the facts of the procedure. General professional standards should not be substituted for an individual legal assessment. The separate UK Position on Who May Inject addresses that topic within its stated limits.

It also does not assess safety, clinical appropriateness, outcomes, treatment areas, dosing, treatment intervals or comparative performance. Those issues are outside the scope of a register of institutional positions. A body's silence cannot be used either way in a consent discussion. Good consent requires discussion of material uncertainty and the actual product and procedure proposed, not an argument from a missing webpage.

Finally, the register does not record internal policies, training-course materials, conference presentations, trade-body commentary, supplier materials, social-media posts or unpublished correspondence. Those may exist, but they are different kinds of material. The inclusion threshold here is a public publication attributable to the named UK institution and readable as a position, guidance document, standards document or patient-information source.

How to use the register in a consultation or complaint

Take the register as a checking tool, not as a substitute for a consultation. If a practitioner says that an institution "recognises", "approves" or "recommends" polynucleotides, ask which institution, which document, which edition and which sentence supports that wording. Write down the answer. A precise citation can be checked against the source's scope. A vague reference to "guidelines" cannot.

If the answer is a general code, ask what practical standard is being relied upon. It may concern competence, record keeping, prescribing, escalation or advertising. That can be relevant. It is nevertheless different from an institutional conclusion about the injectable itself. If the answer is a product-regulation statement, ask whether it concerns that exact product, its intended purpose and its supply route, rather than the category name used in advertising.

Keep copies of consultation notes, consent material, product labels where supplied, aftercare instructions and any correspondence. If a concern later arises, contemporaneous records can help identify what was said and what was done. For suspected adverse reactions, use the publication's guidance on recording a reaction and the appropriate reporting route. Urgent symptoms require urgent clinical assessment rather than a search for institutional position statements.

The register should be reviewed when a named body publishes a dedicated document, updates an existing document, changes the scope of a licensing or regulatory scheme, or removes material. Until then, the careful conclusion is modest: broad UK institutional frameworks exist, but they should not be presented as a dedicated institutional endorsement or assessment of polynucleotide injectables.

Limits of this register

This register applies to public UK institutional material read on 8 November 2026. It is not a live legal database, a product register, a clinical guideline, a list of permitted procedures or a review of every local authority policy. It does not cover non-UK regulators, devolved-nation rules in full, professional associations not listed in the table, insurers, educators, suppliers or individual clinics.

It does not apply to questions about exosomes or vesicle-based products. Those are a different subject area and are not compared here. It also does not analyse body-area advertising, individual indications, treatment selection or claims of benefit. The purpose is narrower: to show what prominent institutions have actually published about polynucleotides, and where a reader should recognise a gap rather than fill it with assumption.

A later document may change an entry. A body may also use different terminology, publish material behind a professional portal, or address a product through a case-specific regulatory action rather than a general publication. Readers relying on the register for a current decision should check the named institution's latest material and retain the date on which they did so.